News | Heart Valve Technology | August 01, 2017

Transcatheter Mitral Valve Repair Start-up CoreMedic Gets Financing

The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing how to install the new chord anchors.

The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing how to install the new chord anchors.

Aug. 1, 2017 — CoreMedic, a start-up developing the ChordArt trancatheter mitral valve repair system, has received investment from the German investment firm SHS Gesellschaft für Beteiligungsmanagement. SHS said it is investing from its fourth fund generation to finance CoreMedic’s further growth and the clinical application of its innovative products. 

Mitral heart valve regurgitation (MR) is one of the most common reasons for cardiac failure. The current gold standard therapy is surgical repair by open heart surgery at the arrested heart. CoreMedic is developing ChordArt, a novel heart valve repair system that is less invasive and easy to use. 

The goal of CoreMedic’s novel medical device is to improve the treatment for patients with mitral heart valve regurgitation. With its minimally invasive approach, ChordArt allows the treatment of patients that are currently excluded from the therapy due to the invasiveness of today’s gold standard, the surgical repair.

CoreMedic will use the raised capital to further develop its ChordArt technologies. A first in human clinical use will be advanced for 2018 as well as the initiation of a clinical trial that will support the European CE mark approval of the product.

“Our novel ChordArt repair concept offers tremendous advantages compared to the currently applied open heart surgery at arrested heart. Due to the significantly reduced invasiveness, the ChordArt approach has not only the potential to allow treatment of currently untreatable patients. It can also reduce the trauma of patients that undergo treatment with today’s gold standard substantially”, said Thomas Bauer, CEO of CoreMedic. “The implant to repair the malfunction of the mitral valve has a minimal footprint and is truly respecting the natural anatomy of the heart. Therefore it is not ‘burning any bridges’ for follow-up treatments that might be required later and is leaving the physician and the patients options that no other device is offering right now.”

SHS Managing Partner Hubertus Leonhardt said the pre-clinical studies have shown that ChordArt incorporates the potential to have an enormous impact on the treatment of structural heart diseases. “We are looking forward to supporting CoreMedic on their path to demonstrate the superiority of the ChordArt system in clinical application and to further develop this novel device,” he said. “We can provide CoreMedic both capital and our industry expertise with an extensive network and over 20 years of experience in the medical technology and life-science sector.”

With a total volume of 125 million euro, the fourth SHS fund is focusing on expansion financing, changes in shareholder structures and successor situations. The Tuebingen based investor is planning further acquisitions and investments in the fast-growing medical technology and life-science industries in Germany, Austria and Switzerland in the months ahead. 

CoreMedic was founded in 2012 in Bern, Switzerland and is a privately help medical device company with locations in Biel, Switzerland and Tuebingen, Germany.

For more information: visit www.coremedic.ch 

Related Content

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Overlay Init